hotspot -WSS

hotspot

author：leisure time 2025-09-27 13:11:05 - browse：417

illustration of a colorful DNA strand, partly broken into pieces. -- health coverage from STAT — Adobe

BALTIMORE — An ambitious effort to cure HIV with CRISPR genome editing fell short in an early clinical trial, investigators announced Friday morning.

In the study, run by Excision BioTherapeutics, researchers tried to use the gene editing tool to address a chief reason HIV has been so hard to cure. While antiviral drugs can clear patients of replicating virus, HIV is able to worm its way into a patients’ own DNA in certain cells. If the patient ever stops taking medicines, those cells start pumping out HIV particles and the infection roars back.

Researchers hoped they could send CRISPR to those cells and, by cutting the HIV DNA lurking there at two spots, slice out the virus. In the Phase 1 trial, investigators administered the treatment to five patients. They then took three of them off conventional antiviral treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Anavex keeps shifting the goalposts in its clinical trials

hotspot

WSS

Wegovy, Zepbound and weight loss drugs that preserve muscle

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Weight loss drug costs may need more research, senator suggests

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Friends ask where James Watson's attitudes about race came from

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

In age of alternative facts, a scholarly course on calling out crap

Surge of respiratory disease in China has likely explanation

Trump demands the U.S. pay no more for drugs than other countries … again

In same hospitals, Black patients receive fewer opioids than white patients

Medicare proposal to cover medical devices draws a mixed reaction

Morphosys mixed study results for blood cancer drug

Hollywood unions extend contract negotiations for actors

David Sabatini, ex

entertainment

Why failed clinical trials don’t always spell doom for a new drug

Hospitals look to new technology to keep health care workers safe

NIH trials fail to test meaningful long Covid therapies, experts say

PBM reforms clear House panel

Wegovy trial has doctors encouraged over new possibilities

Anavex keeps shifting the goalposts in its clinical trials

hotspot

hotspot

hotspot

leisure time